Dacarbazine MEDAC

Therapeutic Indication:

Dacarbazine is indicated for the treatment of patients with metastasized malignant melanoma.
Further indications for Dacarbazine as part of a combination chemotherapy are:

• Advanced Hodgkin’s disease as a second line.
• Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma).

• Composition: Oxaliplatin 5 mg/ml.
• Pharmaceutical Form: Powder for Solution for Infusion.
• Method of Administration: Intravenous.
• How Supplied: Single vials of 200 mg, 500 mg and 1000 mg.
• Manufacturer: Medac GmbH, Germany.